Request Expert

Expert is the Principal and Consultant at a consulting company. The company provides advisory and consultancy services in the areas of drug discovery, therapeutic polymers and biomaterials. He has extensive experience in these areas and co-invented eight therapeutic polymers to reach clinical trials, three of which are approved worldwide (Renagel, Renvela, and Welchol/Cholestagel). He is an inventor on 72 issued US patents and the author of more than 30 publications in these areas. His clients include small and large pharma companies, startups, venture capital firms, and government agencies.

Prior to this he was a Co-Founder and the Chief Technology Officer at a large biomaterials and neuroscience company. He was responsible for helping start it and fulfill its corporate objectives of providing research and development of biomaterials as drug delivery systems for epilepsy, spinal cord injury, pain, and Parkinson's disease. Expert was responsible for developing the technical approaches, hiring the initial team of scientists and engineers, and leading the R&D efforts.

Before the neuroscience company, he was a Vice President and Distinguished Scientific Fellow at Genzyme. For several years, he led the Therapeutic Polymer and Biomaterial Portfolio of research programs. In that role, he was responsible for managing multiple biomaterial and polymer research programs (classified as both drugs and devices), handling the budgeting and prioritization for the programs, and developing new programs. He co-invented many therapies at Genzyme, and was extensively involved in intellectual property and regulatory filings, including presenting technical data to the FDA, and representing Genzyme in two trials relating to generic competitors. He participated on the internal review committee which oversaw the technical aspects of all Genzyme research programs. He also has experience in market assessment, target validation, test method development (in vivo and in vitro), candidate evaluation, and development of drug product profiles.

Expert was the second employee of GelTex Pharmaceuticals, a startup with the mission to develop therapeutic polymers. Genzyme acquired GelTex in 2000 for ~ $1.25 billion, largely based on the value of two therapeutic polymers that he co-invented (Renagel and Welchol). He rose to the position of Director of Chemical Research where he led the chemistry effort to develop novel therapeutics.

Expert also has experience in applied research involving polymer interfaces, surface chemical bonding, and adhesives from his jobs at GTE Laboratories and Lord Corporation.

Expert holds a Ph.D. degree in Chemistry from Harvard University where he studied the surface science of polymers, and a BA with a dual major in Chemistry and Biology from Cornell University.